Last reviewed · How we verify
Xocova (ENSITRELVIR)
At a glance
| Generic name | ENSITRELVIR |
|---|---|
| Sponsor | Shionogi & Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| Annual revenue | 400 |
Approved indications
- Disease caused by Severe acute respiratory syndrome coronavirus 2
Common side effects
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir) (PHASE3)
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (PHASE3)
- Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection (PHASE3)
- A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants (PHASE1)
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID (PHASE2)
- A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants (PHASE1)
- A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xocova CI brief — competitive landscape report
- Xocova updates RSS · CI watch RSS
- Shionogi & Co., Ltd. portfolio CI